Jonelle Claricia Bedford, | |
601 S Martin Luther King Jr Dr, Winston Salem, NC 27110-0003 | |
(336) 750-3174 | |
Not Available |
Full Name | Jonelle Claricia Bedford |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 601 S Martin Luther King Jr Dr, Winston Salem, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013521079 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | (* (Not Available)) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jonelle Claricia Bedford, 601 S Martin Luther King Jr Dr, Winston Salem, NC 27110-0003 Ph: () - | Jonelle Claricia Bedford, 601 S Martin Luther King Jr Dr, Winston Salem, NC 27110-0003 Ph: (336) 750-3174 |
News Archive
Medical devices implanted in the body for drug delivery, sensing, or tissue regeneration usually come under fire from the host's immune system.
A Phase 1 clinical trial testing the safety and effectiveness of a monoclonal antibody (mAb) against malaria has begun enrolling healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial, sponsored by NIH's National Institute of Allergy and Infectious Diseases (NIAID), is the first to test mAb CIS43LS in humans. It aims to enroll up to 73 volunteers aged 18 through 50 years old who have never had malaria.
A review article by researchers at Boston University School of Medicine (BUSM) proposes a new epigenetic hypothesis linked to tumor production and novel ideas about what causes progenitor cells to develop into cancer cells. Published in the February 2013 issue of Epigenomics, the article provides examples of how epigenetic drug treatments could be beneficial in treating cancers while also decreasing the likelihood of cancer relapse.
George Washington University researchers received a $2.2 million grant from the National Cancer Institute to uncover why certain cancer types increase whereas others are unchanged or even decrease in those with HIV infection.
› Verified 1 days ago